Lilly Retatrutide Phase 3 Safety Profile
Decision brief
Answer first · skim in under a minute
TRIUMPH-1: retatrutide 12 mg delivered 28.3% weight loss at 80 weeks with dose-related GI events and discontinuations up to 11.3%.
Eli Lilly’s Phase 3 TRIUMPH-1 program for retatrutide, a GIP/GLP-1/glucagon triple agonist, delivered up to 28.3% mean weight loss at 80 weeks on the 12 mg dose. This analysis separates primary efficacy and safety signals from secondary commentary and maps competitive implications for BD teams tracking Eli Lilly retatrutide Phase 3 versus dual agonists.
Contents10 sections
Key Takeaways
- Lilly’s May 21, 2026 PR Newswire topline said retatrutide 12 mg produced 70.3 lbs (28.3%) mean weight loss at 80 weeks; 9 mg produced 64.4 lbs (25.9%); 4 mg produced 47.2 lbs (19.0%).
- 45.3% of participants on 12 mg achieved ≥30% weight loss; 65.3% reached BMI <30 at 80 weeks, per the same release.
- TRIUMPH-1 is NCT05929066 on ClinicalTrials.gov and enrolled adults with obesity or overweight without diabetes for the obesity primary analysis.
- Phase 2 NEJM data (48 weeks) already showed GI events as the dominant tolerability theme; Phase 3 cardiovascular outcome readouts remain outstanding catalysts.
What did Lilly report from TRIUMPH-1?
In a May 21, 2026 PR Newswire release, Eli Lilly said TRIUMPH-1 evaluated once-weekly retatrutide in adults with obesity or overweight and at least one weight-related comorbidity without diabetes. All doses (4 mg, 9 mg, and 12 mg) met primary and key secondary obesity endpoints at 80 weeks.
Mean baseline weight was about 112.7 kg with BMI 40.0 kg/m². On the efficacy estimand, placebo mean loss was about 2.2% (5.5 lbs). A pre-specified extension for BMI ≥35 on continued 12 mg dosing reported about 85.0 lbs (30.3%) mean loss at 104 weeks. Those extension figures should not be mixed with the 80-week primary table.
How should teams read the safety and tolerability signal?
Lilly’s topline framed gastrointestinal events—nausea, vomiting, diarrhea—as consistent with incretin-based therapies and did not claim a novel organ-toxicity signal in the public summary. Investors still need full adverse-event tables, discontinuation rates, and adjudication of serious events when detailed ADA or journal packages appear.
Earlier Phase 2 evidence in the New England Journal of Medicine report (PubMed 37366315) showed substantial 48-week weight loss with retatrutide and a GI-event profile familiar to GLP-1 class observers. Phase 3 does not erase the need for long-term cardiovascular outcomes data before payer and label assumptions harden.
Where is the trial registered and what is next?
ClinicalTrials.gov lists the pivotal obesity study as NCT05929066 (retatrutide / LY3437943). Lilly’s program narrative points to additional TRIUMPH studies in type 2 diabetes and established cardiovascular disease, with further 2026 readouts anticipated in company communications.
Regulatory filing timing is a commercial assumption, not an FDA decision. Teams should track Lilly’s SEC disclosures for manufacturing capacity and obesity franchise commentary rather than treating media paraphrases of “2027 filing” as primary fact unless restated in a company filing or wire.
Lilly’s public company filings are indexed on the SEC EDGAR company page for CIK 0000059478.
What are the competitive implications versus dual agonists?
Retatrutide’s triple receptor design is positioned against dual GIP/GLP-1 agents such as tirzepatide and against single GLP-1 agonists. TRIUMPH-1’s 28.3% mean loss at 80 weeks raises the efficacy bar for late-stage obesity assets, but head-to-head superiority is not proven by cross-trial comparison.
- Efficacy: high-dose triple agonist outcomes approach bariatric-surgery percentage thresholds Lilly itself referenced (≥30% loss in 45.3% of 12 mg participants).
- Tolerability: GI class effects remain the practical limiter for titration and persistence.
- Access: supply, price, and CV outcomes will decide share more than topline percentage points alone.
Which cardiovascular markers moved in the topline?
Lilly’s release said retatrutide showed significant improvements from baseline across certain cardiovascular risk factors, including waist circumference, non-HDL cholesterol, triglycerides, systolic blood pressure, and high-sensitivity C-reactive protein (hsCRP). Those are biomarker and anthropometric shifts, not adjudicated major adverse cardiovascular events.
BD teams should keep biomarker improvements in a separate column from outcomes-trial endpoints that payers will eventually demand for broad coverage in high-risk populations.
What remains unproven?
Topline Phase 3 obesity efficacy does not prove cardiovascular risk reduction, oral formulation readiness, or superiority to tirzepatide in a randomized head-to-head trial. Delete unsourced claims that retatrutide is “already safer than Zepbound” or that an oral retatrutide launch date is set.
Related NovaPharma coverage
- MariTide Phase 2 obesity data
- Eli Lilly pipeline and deals: 2026 outlook
- Retatrutide Phase 3 results and market impact
Frequently Asked Questions
What did TRIUMPH-1 show for retatrutide 12 mg?
Lilly’s May 21, 2026 PR Newswire release stated that participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks, with 45.3% achieving at least 30% weight loss on the efficacy estimand.
What is the ClinicalTrials.gov identifier for TRIUMPH-1?
TRIUMPH-1 is registered as NCT05929066, a Phase 3 study of retatrutide (LY3437943) in participants with obesity or overweight.
How does Phase 2 inform Phase 3 safety expectations?
A 2023 New England Journal of Medicine Phase 2 study (PubMed 37366315) reported substantial 48-week weight reductions with retatrutide and gastrointestinal events typical of incretin therapies, setting the class-safety baseline investors still use.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for retatrutide.
Unlock full calendar →Eli Lilly pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
Deeper reading
Industry reports & whitepapers
- Ensuring Compatibility for GLP-1-based Drugs — The rise of GLP-1 agonists like Semaglutide demands innovative ready-to-use cartridges to enhance de…